Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ali focuses
Transformative AI in Medical Physics with Dr. Issam El Naqa
On this episode of FYI, Director of Next Generation Internet Research Frank Downing and Analyst Ali Urman interview Dr. Issam El Naqa, the founding chair of the Department of Machine Learning at the Moffitt Cancer Center. Dr. El Naqa shares his journey from electrical engineering to spearheading innovative uses of artificial intelligence (AI) in medical physics and oncology.
#407: The Dencun Upgrade Is An Important Step Toward Scaling Ethereum’s Network, & More
In 2021, CAR-T cell therapy gained acclaim after scientists demonstrated complete remission rates in the 62% to 95% range when used to target CD19 in patients whose acute lymphoblastic leukemia had relapsed.vii Last year, ARK highlighted the story of Alyssa, a 13-year-old girl in the UK who had been diagnosed with T-Cell Acute Lymphoblastic Leukemia, a type of cancer that affects the immune system. CAR-T cell therapy treatment wiped out Alyssa’s cancer.
#407: The Dencun Upgrade Is An Important Step Toward Scaling Ethereum’s Network, & More
In 2021, CAR-T cell therapy gained acclaim after scientists demonstrated complete remission rates in the 62% to 95% range when used to target CD19 in patients whose acute lymphoblastic leukemia had relapsed.vii Last year, ARK highlighted the story of Alyssa, a 13-year-old girl in the UK who had been diagnosed with T-Cell Acute Lymphoblastic Leukemia, a type of cancer that affects the immune system. CAR-T cell therapy treatment wiped out Alyssa’s cancer.
Resurrecting the Woolly Mammoth: CEO Ben Lamm's Colossal Quest
In this episode of For Your Innovation, Ali Urman chats with Ben Lamm, CEO of Colossal, about the groundbreaking venture aimed at resurrecting extinct species, starting with the woolly mammoth. Lamm shares insights into his journey from tech to biotech, highlighting the fusion of artificial intelligence (AI), automation, and genetic editing to challenge the boundaries of science and conservation.
$7 Trillion For Chips and Drug Pricing | The Brainstorm EP 35
$7 trillion for an AI chip? This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nick Grous are joined by Chief Futurist Brett Winton and Multi-Omics Analyst Ali Urman. Together they discuss Sam Altman's plan to raise $7 trillion for an AI chip, and drug pricing.
#402: Token Extensions On The Solana Blockchain Are Unleashing Opportunities For Developers, And More...
Last week, the CEOs of Bristol Myers Squibb (BMY), Merck (MRK), and Johnson and Johnson (JNJ) testifiedvi before the US Senate Committee on Health, Education, Labor and Pensions. The debate centered on why the US is paying the highest prices in the world for many drugs, including Bristol Myers Squibb’s Eliquis, Merck’s Keytruda, and Johnson and Johnson’s Stelara.
#401: Is Meta Disrupting The Consumer Hardware Duopoly?, & More
Surpassing an important milestone in Elon Musk’s quest to create brain-machine interfaces (BMIs),[viii] Neuralink’s robots have inserted[ix] a chip, flush into a persons’ skull. For some perspective, please see the size of the chip below. Source: Chappell 2024.[x] For informational purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security.
#398: Spot Bitcoin ETFs Have Launched, & More
Last week, AI startup Rabbit released its first consumer product, Rabbit R1, as shown below. Source: Rabbit. For illustrative purposes only and should not be considered investment advice or a recommendation to buy, sell, or hold any particular security. Central to R1’s appeal is its Large Action Model (LAM),[xii] a new foundation model that leapfrogs the simple conversational capabilities of traditional chatbots like ChatGPT by enabling specific, app-based tasks.
Crispr Approval, Gemini, and Grok | The Brainstorm EP 27
The FDA Has Approved America’s First Gene-Editing Therapy—Casgevy. This week, Autonomous Technology and Robotics Director of Research Sam Korus and Associate Portfolio Manager Nick Grous are joined by Ali Urman, ARK Analyst. Together they discuss a Crispr gene editing breakthrough.
#395: The FDA Has Approved America’s First Gene-Editing Therapy-Casgevy, & More
Two weeks ago, the Institute for Intelligent Computing and Alibaba Group published an image-to-video model called Animate Anyone.[xv] The model transforms an input reference image and a pose sequence into a video. Unlike in previous image-to-video research, Animate Anyone introduced a feature extraction network called ReferenceNet that captures details from the original reference image in each video frame generated.
#394: Are We Asking AI Models the Right Questions?, & More
While artificial intelligence (AI) language models can improve in many ways, a recent paperi by researchers from Microsoft and OpenAI illustrates the importance of posing questions to models in the right way. As shown below in the gray dotted line on the left, earlier this year smaller AI models “fine-tuned” on specialized data caught up to OpenAI's state-of-the-art GPT-4 model on a medical licensing exam test.
#391: Jack Dorsey Is Back In The Saddle At Block, & More
Last week, the Biden Administration issued a broad Executive Order[iv] related to artificial intelligence (AI), effective immediately, with compliance deadlines in the next three to nine months. The order subjects all private large training models to reporting and testing requirements and requires cloud computing and other large datacenter providers to validate and monitor customer identity and behavior. The order also places stringent requirements on AI systems that use biological data.
November 3, 2023 — In The Know with Cathie Wood -
On episode XLIX of “In the Know,” (November 3, 2023) ARK CEO/CIO, Cathie Wood, weighs in on risks of inflation vs. deflation, currencies as flights to safety, and what’s contributing to this rolling recession. Cathie is also joined by ARK Analyst, Ali Urman, who shares exciting and hopeful news within the multi-omics space – specifically regarding gene-editing treatments for sickle-cell disease and beta thalassemia. (Please find the full video Ali references here).
#389: Could ChatGPT Become A Decision Support Tool For Medical Practitioners? , & More - ARK Invest
During Tesla’s earnings call last week, CEO Elon Musk warned investors that, although the Cybertruck would debut commercially on November 30, scaling volume production would be “enormously challenging.” Tesla has lots of experience with difficult volume production ramps.
Ozempic, AI Wearables, Tesla Price Cuts | The Brainstorm EP 18
If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn’t mean we don’t have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we’re sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Public.com.
#387: Immersive Audiovisual AI Applications Could Dominate Online Consumer Platforms, & More
Tesla’s move could be a leading indicator of a broader decline in auto prices, spelling more trouble for parts of the industry facing strikes and higher wage gains. According to Wright’s Law[14], electric vehicle prices should continue to decline in tandem with battery and other input costs. [1] Biino, M. 2023. “How Much Money OnlyFans Creators Make.” Business Insider. BamSEC. 2023a. “FY 2022 10-K Filing, Bumble Inc.” BamSEC. 2023b. “FY 2022 10-K Filing, Match Group Inc.” BamSEC. 2023c.
Shaping the Immunotherapy Landscape with Patrick Hwu, MD
Shaping the Immunotherapy Landscape with Patrick Hwu, MD Immunotherapy has the potential to cure cancer. Today we are joined by a leading figure in cancer studies and research and one who has helped shape the immunotherapy landscape, Dr. Patrick Hwu. The internationally recognized Dr. Hwu previously applied his trade at the National Cancer Institute and is now the President and CEO of one of America’s leading cancer hospitals, the Moffitt Cancer Center.
Gene Editing: A Primer
In 1953, the discovery of DNA’s structure and function galvanized innovation in genetics—the study of genes, genetic variation, and heredity. Yet, many foundational concepts in genetics, gene sequencing, and gene editing have been difficult to grasp, until recently (Pray 2008). In hopes of curing disease, Emmanuelle Charpentier and Jennifer Doudna developed a revolutionary gene-editing method called CRISPR/Cas9 and won the Nobel Prize in Chemistry in 2020 (NobelPrize.org 2020).
Programming Medicine with Dr. Jonathan Weissman
Programming Medicine with Dr. Jonathan Weissman We are very excited to be joined today by one of the world’s leaders in scientific and biological research, Dr. Jonathan Weissman. After a breakdown of Jonathan’s professional background, we dive into CRISPR and how the genetic engineering tool can be used for drug development, disease discovery, and as a therapeutic treatment of its own.
Big Ideas Monday Mini: Precision Therapies
Welcome to the Big Ideas Monday Miniseries, brought to you by the For Your Innovation Podcast. Big Ideas is meant to enlighten investors on the long-term impact of innovation. This annual research report seeks to highlight the technological breakthroughs evolving today and creating the potential for super-exponential growth tomorrow. We believe that innovation is taking off now, corroborating our original research and boosting our confidence that ARK’s strategies are on the right side of change.
#366: Does An Influencer’s AI Counterpart Signal The Return Of The 1-900 Number?, & More
1. Does An Influencer’s AI Counterpart Signal The Return Of The 1-900 Number? Snapchat influencer Caryn Marjorie, 23 years old, recently ventured into the AI space with a virtual version of herself.1 Powered by OpenAI and designed to simulate a virtual girlfriend, CarynAI charges $1 per minute for interactions and, in just one week of beta testing, generated $71,610 from its predominantly male user base.
Gene Therapy Could Cure Cancer with Professor Waseem Qasim
Gene Therapy Could Cure Cancer with Professor Waseem Qasim Gene therapy is gaining momentum as a noteworthy adversary to cancer, and we are thrilled to be joined today by one of the pioneers of immune system-based treatments. Professor Waseem Qasim applies his craft at the UCL Great Ormond Street Institute of Child Health, which is notorious for being the largest concentration of children’s health research in Europe.
Precision Therapies
Generative AI made waves this year, from DALL-E-2 to ChatGPT. These tools are improving the productivity of knowledge workers—~2x in the case of AI coding assistants. AI training cost declines continued at an annual rate of 70%, the cost to train a large language model to GPT-3 level performance collapsing from $4.6 million in 2020 to $450,000 in 2022. We expect cost declines to continue at a 70% rate through 2030. AI should increase the productivity of knowledge workers more than 4-fold by 2030.
A New Era in Cancer Immunotherapy with Tom Whitehead and Dr. Alex Marson
A New Era in Cancer Immunotherapy with Tom Whitehead and Dr. Alex Marson When his six-year-old daughter was diagnosed with acute lymphoblastic leukemia, Tom Whitehead was determined to do whatever it took to save her life. In 2012, Emily Whitehead became the first patient enrolled in a clinical trial of a new immunotherapy treatment known as CAR T, which would ultimately turn her immune system into a powerful weapon against cancer.
Breaking Down Biotech Innovations with Dr. Bob Langer
Breaking Down Biotech Innovations with Dr. Bob Langer Today’s guest is MIT professor, chemical engineer, scientist, inventor, and investor Dr. Bob Langer. Dr. Langer has over 1,400 granted or pending patents and has been cited 374,000 times (and counting)! As a co-founder of Moderna, he has great insights into the potential of mRNA to treat diseases of various descriptions. Joining us to pick this extraordinary mind is clinically trained entrepreneur, Dr. Charlie Roberts.
Inventing Base Editing with Doctors Nicole Gaudelli and Alexis Komor
Please note: as of 6/30/22, ARK’s clients own greater than 1% of the shares outstanding of Beam Therapeutics Inc. On today’s episode, ARK analyst Ali Urman hosts the inventors of the adenine base editor (ABE) and the cytosine base editor (CBE) Nicole Gaudelli and Alexis Komor, respectively.
Gene Editing Outcomes Vary By Technology
In the process of gene editing, scientists try to cure disease by using molecular tools to insert, delete, or change DNA in a precise way. The rise of breakthrough gene editing technologies has revolutionized our ability to study and treat diseases. All gene-editing agents must accomplish two goals: 1) find a DNA sequence, and 2) change that target DNA’s sequence.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ali
Contact Ali, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack